Which has higher valuation & earnings, ERAS or RVMD?

Revolution Medicines is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Erasca N/A N/A -$124.55M -$0.93 N/A Revolution Medicines N/A N/A -$1.13B -$7.07 N/A

Is ERAS or RVMD more profitable?

Erasca's return on equity of -35.31% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% Revolution Medicines N/A -83.22% -59.06%

Does the media favor ERAS or RVMD?

In the previous week, Erasca had 21 more articles in the media than Revolution Medicines. MarketBeat recorded 42 mentions for Erasca and 21 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.39 beat Erasca's score of 0.25 indicating that Revolution Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 9 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Revolution Medicines 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, INSM or ERAS?

Erasca has lower revenue, but higher earnings than Insmed. Erasca is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Insmed $606.42M 35.24 -$1.28B -$5.75 N/A Erasca N/A N/A -$124.55M -$0.93 N/A

Is INSM or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Erasca's return on equity of -35.31% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Insmed -144.44% -130.11% -51.57% Erasca N/A -35.31% -29.49%

Does the media favor INSM or ERAS?

In the previous week, Erasca had 29 more articles in the media than Insmed. MarketBeat recorded 42 mentions for Erasca and 13 mentions for Insmed. Insmed's average media sentiment score of 1.30 beat Erasca's score of 0.25 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 10 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Erasca 9 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ERAS or BNTX more profitable?

Erasca has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -35.31% -29.49% BioNTech -44.39% -5.30% -4.62%

Does the media refer more to ERAS or BNTX?

In the previous week, Erasca had 36 more articles in the media than BioNTech. MarketBeat recorded 42 mentions for Erasca and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.86 beat Erasca's score of 0.25 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 9 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MRNA or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% Erasca N/A -35.31% -29.49%

Does the media prefer MRNA or ERAS?

In the previous week, Moderna had 4 more articles in the media than Erasca. MarketBeat recorded 46 mentions for Moderna and 42 mentions for Erasca. Moderna's average media sentiment score of 0.38 beat Erasca's score of 0.25 indicating that Moderna is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 15 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 9 Negative mention(s) 1 Very Negative mention(s) Neutral Erasca 9 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VTRS or ERAS more profitable?

Erasca has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Erasca N/A -35.31% -29.49%

Does the media prefer VTRS or ERAS?

In the previous week, Erasca had 37 more articles in the media than Viatris. MarketBeat recorded 42 mentions for Erasca and 5 mentions for Viatris. Viatris' average media sentiment score of 0.39 beat Erasca's score of 0.25 indicating that Viatris is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 9 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Erasca (ERAS) Competitors

$18.15 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$17.90 -0.25 (-1.40%)

As of 07/31/2026 07:34 PM Eastern

Compare

ERAS vs. RVMD, INSM, BNTX, MRNA, and VTRS

Should you buy Erasca stock or one of its competitors? MarketBeat compares Erasca with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Erasca include Revolution Medicines (RVMD), Insmed (INSM), BioNTech (BNTX), Moderna (MRNA), and Viatris (VTRS).

How does Erasca compare to Revolution Medicines?

Erasca (NASDAQ:ERAS) and Revolution Medicines (NASDAQ:RVMD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Revolution Medicines is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Revolution Medicines	N/A	N/A	-$1.13B	-$7.07	N/A

In the previous week, Erasca had 21 more articles in the media than Revolution Medicines. MarketBeat recorded 42 mentions for Erasca and 21 mentions for Revolution Medicines. Revolution Medicines' average media sentiment score of 1.39 beat Erasca's score of 0.25 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	9 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	17 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca's return on equity of -35.31% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Revolution Medicines	N/A	-83.22%	-59.06%

67.8% of Erasca shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Erasca has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Erasca presently has a consensus target price of $21.64, suggesting a potential upside of 19.21%. Revolution Medicines has a consensus target price of $144.67, suggesting a potential downside of 22.85%. Given Erasca's higher probable upside, equities research analysts plainly believe Erasca is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.95

Summary

Erasca beats Revolution Medicines on 8 of the 14 factors compared between the two stocks.

How does Erasca compare to Insmed?

Insmed (NASDAQ:INSM) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, valuation, dividends and risk.

In the previous week, Erasca had 29 more articles in the media than Insmed. MarketBeat recorded 42 mentions for Erasca and 13 mentions for Insmed. Insmed's average media sentiment score of 1.30 beat Erasca's score of 0.25 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	10 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	9 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Erasca has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Erasca's return on equity of -35.31% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
Erasca	N/A	-35.31%	-29.49%

Insmed currently has a consensus target price of $209.35, indicating a potential upside of 112.32%. Erasca has a consensus target price of $21.64, indicating a potential upside of 19.21%. Given Insmed's stronger consensus rating and higher probable upside, equities research analysts plainly believe Insmed is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

67.8% of Erasca shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Erasca has lower revenue, but higher earnings than Insmed. Erasca is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	35.24	-$1.28B	-$5.75	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Summary

Insmed and Erasca tied by winning 8 of the 16 factors compared between the two stocks.

How does Erasca compare to BioNTech?

Erasca (NASDAQ:ERAS) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

Erasca has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
BioNTech	-44.39%	-5.30%	-4.62%

Erasca has higher earnings, but lower revenue than BioNTech. Erasca is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
BioNTech	$3.25B	7.06	-$1.29B	-$5.88	N/A

67.8% of Erasca shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Erasca has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

Erasca currently has a consensus target price of $21.64, suggesting a potential upside of 19.21%. BioNTech has a consensus target price of $129.13, suggesting a potential upside of 42.55%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74

In the previous week, Erasca had 36 more articles in the media than BioNTech. MarketBeat recorded 42 mentions for Erasca and 6 mentions for BioNTech. BioNTech's average media sentiment score of 0.86 beat Erasca's score of 0.25 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	9 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats Erasca on 11 of the 16 factors compared between the two stocks.

How does Erasca compare to Moderna?

Moderna (NASDAQ:MRNA) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Erasca has lower revenue, but higher earnings than Moderna. Erasca is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	11.19	-$2.82B	-$8.15	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

75.3% of Moderna shares are held by institutional investors. Comparatively, 67.8% of Erasca shares are held by institutional investors. 10.8% of Moderna shares are held by company insiders. Comparatively, 14.2% of Erasca shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Moderna had 4 more articles in the media than Erasca. MarketBeat recorded 46 mentions for Moderna and 42 mentions for Erasca. Moderna's average media sentiment score of 0.38 beat Erasca's score of 0.25 indicating that Moderna is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	15 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Neutral
Erasca	9 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Moderna has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Erasca has a net margin of 0.00% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
Erasca	N/A	-35.31%	-29.49%

Moderna presently has a consensus target price of $40.00, indicating a potential downside of 27.03%. Erasca has a consensus target price of $21.64, indicating a potential upside of 19.21%. Given Erasca's stronger consensus rating and higher possible upside, analysts clearly believe Erasca is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Summary

Moderna beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Erasca compare to Viatris?

Viatris (NASDAQ:VTRS) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Erasca has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.30B	1.43	-$3.51B	-$0.26	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Viatris currently has a consensus price target of $17.50, indicating a potential downside of 0.34%. Erasca has a consensus price target of $21.64, indicating a potential upside of 19.21%. Given Erasca's stronger consensus rating and higher probable upside, analysts clearly believe Erasca is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

Erasca has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Erasca	N/A	-35.31%	-29.49%

Viatris has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Erasca has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 0.3% of Viatris shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Erasca had 37 more articles in the media than Viatris. MarketBeat recorded 42 mentions for Erasca and 5 mentions for Viatris. Viatris' average media sentiment score of 0.39 beat Erasca's score of 0.25 indicating that Viatris is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	9 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Erasca beats Viatris on 8 of the 15 factors compared between the two stocks.

Get Erasca News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ERAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ERAS vs. The Competition

Export

Metric	Erasca	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.64B	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-19.52	7.38	282.27	24.66
Price / Sales	N/A	1,273.79	590.91	92.54
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	17.29	16.78	10.93	6.07
Net Income	-$124.55M	-$12.56M	$3.49B	$347.99M
7 Day Performance	-3.82%	-1.82%	-0.64%	-0.42%
1 Month Performance	-1.73%	-8.45%	-3.78%	-4.80%
1 Year Performance	1,205.76%	48.33%	61.99%	18.61%

Erasca Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ERAS Erasca	2.3319 of 5 stars	$18.15 flat	$21.64 +19.2%	+1,205.8%	$5.64B	N/A	N/A	120	Trending News Gap Up
RVMD Revolution Medicines	1.7953 of 5 stars	$189.23 +0.3%	$144.67 -23.5%	+412.0%	$40.13B	$11.58M	N/A	250	Positive News Upcoming Earnings Gap Up
INSM Insmed	3.8307 of 5 stars	$106.92 -0.5%	$209.13 +95.6%	-9.3%	$23.28B	$606.42M	N/A	1,664	Positive News Upcoming Earnings Gap Up
BNTX BioNTech	3.9423 of 5 stars	$89.33 -3.0%	$129.13 +44.5%	-15.6%	$23.28B	$3.25B	N/A	7,807	Upcoming Earnings
MRNA Moderna	1.3283 of 5 stars	$54.07 -5.2%	$40.00 -26.0%	+98.6%	$22.62B	$1.94B	N/A	4,700	Trending News Earnings Report Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ERAS) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Erasca (ERAS) Competitors

ERAS vs. RVMD, INSM, BNTX, MRNA, and VTRS

How does Erasca compare to Revolution Medicines?

Summary

How does Erasca compare to Insmed?

Summary

How does Erasca compare to BioNTech?

Summary

How does Erasca compare to Moderna?

Summary

How does Erasca compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Erasca (ERAS) Competitors

ERAS vs. RVMD, INSM, BNTX, MRNA, and VTRS

How does Erasca compare to Revolution Medicines?

Which has higher valuation & earnings, ERAS or RVMD?

Does the media favor ERAS or RVMD?

Is ERAS or RVMD more profitable?

Do institutionals and insiders have more ownership in ERAS or RVMD?

Which has more risk & volatility, ERAS or RVMD?

Do analysts prefer ERAS or RVMD?

Summary

How does Erasca compare to Insmed?

Does the media favor INSM or ERAS?

Is INSM or ERAS more profitable?

Do analysts rate INSM or ERAS?

Which has more volatility and risk, INSM or ERAS?

Do insiders and institutionals believe in INSM or ERAS?

Which has higher valuation and earnings, INSM or ERAS?

Summary

How does Erasca compare to BioNTech?

Is ERAS or BNTX more profitable?

Which has stronger valuation and earnings, ERAS or BNTX?

Do insiders & institutionals have more ownership in ERAS or BNTX?

Which has more risk and volatility, ERAS or BNTX?

Do analysts prefer ERAS or BNTX?

Does the media refer more to ERAS or BNTX?

Summary

How does Erasca compare to Moderna?

Which has preferable valuation and earnings, MRNA or ERAS?

Do insiders and institutionals believe in MRNA or ERAS?

Does the media prefer MRNA or ERAS?

Which has more risk & volatility, MRNA or ERAS?

Is MRNA or ERAS more profitable?

Do analysts prefer MRNA or ERAS?

Summary

How does Erasca compare to Viatris?

Which has stronger earnings and valuation, VTRS or ERAS?

Do analysts recommend VTRS or ERAS?

Is VTRS or ERAS more profitable?

Which has more risk & volatility, VTRS or ERAS?

Do institutionals & insiders believe in VTRS or ERAS?

Does the media prefer VTRS or ERAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERAS vs. The Competition

Erasca Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools